Targeting the tumor microenvironment of Ewing sarcoma

被引:6
|
作者
Morales, Erin [1 ]
Olson, Michael [2 ,3 ]
Iglesias, Fiorella [4 ]
Luetkens, Tim [5 ,6 ,7 ]
Atanackovic, Djordje [5 ,6 ,7 ]
机构
[1] Univ Utah, Pediat Hematol Oncol Dept, Salt Lake City, UT 84132 USA
[2] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA
[3] Univ Utah, Huntsman Canc Inst, Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA
[5] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[6] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[7] Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
关键词
cancer vaccines; CAR T cells; chemokines; cytokines; Ewing sarcoma; immune checkpoint inhibition; immune escape; immunosuppression; immunotherapy; microenvironment; monoclonal antibodies; T cells; TCR-transduced T cells; tumor immunology; tumor microenvironment; REGULATORY T-CELLS; MYELOID SUPPRESSOR-CELLS; EMERGING EFFECTOR-CELLS; NITRIC-OXIDE SYNTHASE; CIRCULATING FIBROCYTES; REACTIVE OXYGEN; ANTITUMOR-ACTIVITY; PERIPHERAL-BLOOD; IMMUNE CELLS; II RECEPTOR;
D O I
10.2217/imt-2020-0341
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lay abstract Ewing sarcoma is an aggressive type of cancer of the bones or soft tissues that mainly affects teenagers. Patients are often treated with intensive treatments which may include chemotherapy in combination with radiation and/or surgery. For patients who present with cancer that has already spread to other sites or that returns after treatment, the cancer can be very hard to cure. This leads to the need for different therapies. Therapies that use the help of the immune system to combat the cancer, called immunotherapies, have had limited success, which is thought to be due to factors in the environment of the tumor that weaken the immune system and so dampen any potential use of it to destroy the cancer cells. We provide an overview of these factors in the tumor environment that allow the cancer cells to escape the immune system; we also discuss potential options to target these factors and, in this way, allow the immunotherapies to destroy the cancer cells more effectively. Ewing sarcoma is an aggressive tumor type with an age peak in adolescence. Despite the use of dose-intensified chemotherapy as well as radiation and surgery for local control, patients with upfront metastatic disease or relapsed disease have a dismal prognosis, highlighting the need for additional therapeutic options. Different types of immunotherapies have been investigated with only very limited clinical success, which may be due to the presence of immunosuppressive factors in the tumor microenvironment. Here we provide an overview on different factors contributing to Ewing sarcoma immune escape. We demonstrate ways to target these factors in order to make current and future immunotherapies more effective and achieve deeper and more durable responses in patients with Ewing sarcoma.
引用
收藏
页码:1439 / 1451
页数:13
相关论文
共 50 条
  • [21] Targeting ribonucleotide reductase (RNR) in Ewing sarcoma
    Goss, Kelli
    Koppenhafer, Stacia
    Harmoney, Kathryn
    Gordon, David
    CANCER RESEARCH, 2017, 77
  • [22] Targeting the dysregulation of transcription and splicing in Ewing sarcoma
    Lawrence, A.
    Miller, Henry
    Bishop, Alexander
    CLINICAL CANCER RESEARCH, 2022, 28 (18)
  • [23] Targeting NAMPT in Ewing's sarcoma cells
    Mutz, Cornelia N.
    Schwentner, Raphaela
    Bouchard, Eric
    Mejia, Edgard M.
    Katschnig, Anna M.
    Kauer, Maximilian .
    Aryee, Dave N. T.
    Garten, Antje
    Banerji, Versha
    Kovar, Heinrich
    CANCER RESEARCH, 2016, 76
  • [24] Targeting Ewing sarcoma based on RNA expression
    Smith, Kaitlyn
    Gandra, Divya
    McKinney, Kimberly
    Dykema, Karl
    Nagulapally, Abhinav
    Sholler, Giselle S.
    Oesterheld, Javier
    Trovillion, Erin
    CANCER RESEARCH, 2022, 82 (12)
  • [25] Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board
    Gupta, Ajay
    Riedel, Richard F.
    Shah, Chirag
    Borinstein, Scott C.
    Isakoff, Michael S.
    Chugh, Rashmi
    Rosenblum, Jeremy M.
    Murphy, Erin S.
    Campbell, Shauna R.
    Albert, Catherine M.
    Zahler, Stacey
    Thomas, Stefanie M.
    Trucco, Matteo
    CANCER, 2023, 129 (21) : 3363 - 3371
  • [26] Targeting the tumor microenvironment
    Kenny, Paraic A.
    Lee, Genee Y.
    Bissell, Mina J.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 3468 - 3474
  • [27] Discrete extracellular matrix-secreting tumor cell subpopulations remodel the Ewing sarcoma tumor microenvironment to promote invasion
    Wrenn, Emma D.
    Apfelbaum, April A.
    Ganapathi, Shireen
    Rudzinski, Erin R.
    Deng, Xuemei
    Garcia, Nicolas
    Braun, Katherine
    Lipson, Trisha
    Bhise, Shruti
    Kanaan, Sami B.
    Waltner, Olivia
    Newman, Erika
    Furlan, Scott
    Lawlor, Elizabeth R.
    CANCER RESEARCH, 2023, 83 (07)
  • [28] Primitive Neuroectodermal Tumor/Ewing Sarcoma of the Retina
    Grossniklaus, Hans E.
    Shehata, Bahig
    Sorensen, Poul
    Bergstrom, Chris
    Hubbard, G. Baker
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (07) : 829 - 831
  • [29] Ewing's sarcoma: an uncommon breast tumor
    Meddeb, Sawsen
    Rhim, Mohamed Salah
    Kouira, Mouna
    Mestiri, Sarra
    Bibi, Mohamed
    Yacoubi, Mohamed Tahar
    CLINICS AND PRACTICE, 2014, 4 (02) : 47 - 49
  • [30] A rare tumor: tracheal Ewing's sarcoma
    Guzeloz, Zeliha
    Elboga, Umut
    Sanli, Maruf
    Bakir, Kemal
    Arslan, Isin
    Dirier, Ahmet
    WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 (9-10) : 259 - 260